(CercleFinance.com) – Eli Lilly announced a major investment of $5.3 billion in its Lebanon (Indiana) manufacturing site, bringing the total investment to $9 billion.
This operation aims to strengthen the production capacity of active pharmaceutical ingredients (API) for Zepbound (tirzepatide) and Mounjaro (tirzepatide), thus providing more capacity for treatments against obesity and type 2 diabetes.
The laboratory specifies that it has invested more than $16 billion since 2020 in new manufacturing sites in the United States and Europe.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
